XM does not provide services to residents of the United States of America.
G
G

GSK

Trade Ideas

Traders Sentiment

Technical Summary

Hourly

News

UK Stocks-Factors to watch on Nov 19

UPDATE 1-UK Stocks-Factors to watch on Nov 19 Adds new items, updates futures Nov 19 (Reuters) - Britain's FTSE 100 .FTSE index is seen opening higher on Tuesday, with futures FFIc1 up 0.45%. * IMPERIAL BRANDS: Cigarette maker Imperial Brands IMB.L reported forecast-beating operating profit and said it expected another strong performance next year, as revenues from smoking alternatives soared 26%.
G
I
I

GSK drug meets main goal in late-stage study to treat relentless itch

GSK drug meets main goal in late-stage study to treat relentless itch Nov 19 (Reuters) - British drugmaker GSK GSK.L said on Tuesday its experimental therapy, linerixibat, met its main goal in a late-stage trial to treat patients with a so-called relentless itch associated with a rare autoimmune liver disease. The drug resulted in an improvement in itch compared to a placebo, GSK said.
G

GSK Meets Primary Endpoint in Late-Stage Trial To Treat Relentless Itch

BRIEF-GSK Meets Primary Endpoint in Late-Stage Trial To Treat Relentless Itch Nov 19 (Reuters) - GSK plc GSK.L : GSK PLC - GLISTEN TRIAL OF LINERIXIBAT MEETS ENDPOINT GSK PLC - GLISTEN TRIAL OF LINERIXIBAT MEETS ENDPOINT GSK PLC - LINERIXIBAT SHOWS POSITIVE PHASE III RESULTS IN PBC ITCH GSK PLC - PRIMARY ENDPOINT MET WITH SIGNIFICANT IMPROVEMENT IN
G

Gsk PLC Reports 9.5% Stake In 23Andme Holding As Of Nov 12 Versus Previous Stake Of 11.2% As Of Feb 7 - SEC Filing

BRIEF-Gsk PLC Reports 9.5% Stake In 23Andme Holding As Of Nov 12 Versus Previous Stake Of 11.2% As Of Feb 7 - SEC Filing Nov 15 (Reuters) - GSK plc GSK.L : GSK PLC REPORTS 9.5% STAKE IN 23ANDME HOLDING AS OF NOV 12 VERSUS PREVIOUS STAKE OF 11.2% AS OF FEB 7 - SEC FILING Source text: [ID:n0001839882-24-039514] Further company coverage: GSK.L
G

Drugmaker stocks slide as Trump taps vaccine skeptic RFK Jr for US health job

UPDATE 7-Drugmaker stocks slide as Trump taps vaccine skeptic RFK Jr for US health job Vaccine skepticism concerns impact biotech investor sentiment Shares of European drug makers fall, along with U.S. companies Analysts worry about RFK Jr.'s influence on HHS agencies Updates throughout with detail on stock moves By Samuel Indyk and Ludwig Burger Nov 15 (Reuters) - Shares of major U.S.
A
G
M
P
P
R
S
C
K
C

Conditions

Popular Assets

Disclaimer: The XM Group entities provide execution-only service and access to our Online Trading Facility, permitting a person to view and/or use the content available on or via the website, is not intended to change or expand on this, nor does it change or expand on this. Such access and use are always subject to: (i) Terms and Conditions; (ii) Risk Warnings; and (iii) Full Disclaimer. Such content is therefore provided as no more than general information. Particularly, please be aware that the contents of our Online Trading Facility are neither a solicitation, nor an offer to enter any transactions on the financial markets. Trading on any financial market involves a significant level of risk to your capital.

All material published on our Online Trading Facility is intended for educational/informational purposes only, and does not contain – nor should it be considered as containing – financial, investment tax or trading advice and recommendations; or a record of our trading prices; or an offer of, or solicitation for, a transaction in any financial instruments; or unsolicited financial promotions to you.

Any third-party content, as well as content prepared by XM, such as: opinions, news, research, analyses, prices and other information or links to third-party sites contained on this website are provided on an “as-is” basis, as general market commentary, and do not constitute investment advice. To the extent that any content is construed as investment research, you must note and accept that the content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, it would be considered as marketing communication under the relevant laws and regulations. Please ensure that you have read and understood our Notification on Non-Independent Investment. Research and Risk Warning concerning the foregoing information, which can be accessed here.

Risk Warning: Your capital is at risk. Leveraged products may not be suitable for everyone. Please consider our Risk Disclosure.